[go: up one dir, main page]

MX2020012065A - Compuestos de ciclopentano. - Google Patents

Compuestos de ciclopentano.

Info

Publication number
MX2020012065A
MX2020012065A MX2020012065A MX2020012065A MX2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A MX 2020012065 A MX2020012065 A MX 2020012065A
Authority
MX
Mexico
Prior art keywords
cyclopentane compounds
cyclopentane
compounds
medicine
processes
Prior art date
Application number
MX2020012065A
Other languages
English (en)
Inventor
Grigorios Nikitidis
Xiaolin Zhang
Weitao Pan
Jenny Susanna Marika Lindhagen
Original Assignee
Dizal Jiangsu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dizal Jiangsu Pharmaceutical Co Ltd filed Critical Dizal Jiangsu Pharmaceutical Co Ltd
Publication of MX2020012065A publication Critical patent/MX2020012065A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing alicyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de ciclopentano de Fórmula (I), formas físicas de los mismos, procesos para su producción y su uso en medicina. (ver Fórmula).
MX2020012065A 2018-05-11 2019-05-09 Compuestos de ciclopentano. MX2020012065A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018086503 2018-05-11
PCT/EP2019/061888 WO2019215268A1 (en) 2018-05-11 2019-05-09 Cyclopentane compounds

Publications (1)

Publication Number Publication Date
MX2020012065A true MX2020012065A (es) 2021-02-26

Family

ID=66542241

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020012065A MX2020012065A (es) 2018-05-11 2019-05-09 Compuestos de ciclopentano.

Country Status (16)

Country Link
US (2) US11274091B2 (es)
EP (1) EP3790870B1 (es)
JP (1) JP7418354B2 (es)
KR (1) KR102806779B1 (es)
CN (1) CN112424182B (es)
AR (1) AR115382A1 (es)
AU (1) AU2019266525B2 (es)
BR (1) BR112020023065A2 (es)
CA (1) CA3099507A1 (es)
DK (1) DK3790870T3 (es)
ES (1) ES2944735T3 (es)
MX (1) MX2020012065A (es)
PT (1) PT3790870T (es)
TW (1) TWI830733B (es)
UY (1) UY38229A (es)
WO (1) WO2019215268A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲（江蘇）醫藥有限公司 環戊烷化合物
JP7594274B2 (ja) 2019-10-24 2024-12-04 国立大学法人大阪大学 難聴の予防および／または治療用医薬組成物
CN121399116A (zh) 2023-07-06 2026-01-23 巴斯夫欧洲公司 用于防治无脊椎有害生物的三唑化合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004017930A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20100234409A1 (en) * 2004-05-21 2010-09-16 Lihu Yang Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
ES2372955T3 (es) * 2006-07-06 2012-01-30 Array Biopharma, Inc. Ciclopenta[d]pirimidinas como inhibidores de la proteína cinasa akt.
PE20091315A1 (es) * 2008-01-09 2009-09-21 Array Biopharma Inc Ciclopentanos de pirimidilo como inhibidores de la proteina cinasa akt
MY152557A (en) * 2008-11-26 2014-10-31 Pfizer 3-aminocyclopentanecarboxamides as chemokine receptor modulators
US7893099B2 (en) * 2009-06-11 2011-02-22 Hoffman-La Roche Inc. Cyclopentane derivatives
EP2368876A1 (en) * 2010-03-01 2011-09-28 Sanofi Derivatives of aminoindanes, their preparation and their application in therapeutics
ES2654471T3 (es) * 2013-06-21 2018-02-13 Merck Patent Gmbh Derivados de la 1,3-diaminociclopentano carboxamida
WO2015014446A1 (en) * 2013-07-29 2015-02-05 Merck Patent Gmbh 1,3-disubstituted cyclopentane derivatives
TWI830733B (zh) * 2018-05-11 2024-02-01 中國大陸商迪哲（江蘇）醫藥有限公司 環戊烷化合物

Also Published As

Publication number Publication date
WO2019215268A1 (en) 2019-11-14
DK3790870T3 (da) 2023-05-08
CN112424182A (zh) 2021-02-26
US12378218B2 (en) 2025-08-05
US11274091B2 (en) 2022-03-15
ES2944735T3 (es) 2023-06-23
KR20210018287A (ko) 2021-02-17
PT3790870T (pt) 2023-05-05
TW202016087A (zh) 2020-05-01
AU2019266525B2 (en) 2024-06-13
JP7418354B2 (ja) 2024-01-19
AU2019266525A1 (en) 2020-11-26
AR115382A1 (es) 2021-01-13
UY38229A (es) 2019-11-29
BR112020023065A2 (pt) 2021-02-02
EP3790870B1 (en) 2023-04-19
US20210070733A1 (en) 2021-03-11
TWI830733B (zh) 2024-02-01
EP3790870A1 (en) 2021-03-17
KR102806779B1 (ko) 2025-05-12
US20220194922A1 (en) 2022-06-23
CN112424182B (zh) 2023-05-23
CA3099507A1 (en) 2019-11-14
JP2021523178A (ja) 2021-09-02

Similar Documents

Publication Publication Date Title
PH12017501921A1 (en) Novel compounds
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
SG10201806849WA (en) Cyclopropylamines as lsd1 inhibitors
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
MX2021001186A (es) Purinonas como inhibidores de proteasa especifica de ubiquitina 1.
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
MX381417B (es) Inhibidores de glucosidasa.
SA518391864B1 (ar) مشتقات باي بيرازوليل مفيدة لمعالجة أمراض المناعة الذاتية
MX2018002899A (es) Tratamiento de retinitis pigmentosa.
EA201691594A1 (ru) Циклопропиламины в качестве ингибиторов lsd1
MX378732B (es) Formas solidas novedosas
NZ726859A (en) Synthesis of polycyclic-carbamoylpyridone compounds
EP4364743A3 (en) A modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders
MX2020006237A (es) Compuestos para el tratamiento de enfermedades relacionadas con la expresion de dux4.
JOP20200110A1 (ar) متبلورات مضادة جديدة لسلسلة من مركبات مضادة للفيروسات
MX373320B (es) Compuestos inhibidores de pde2.
PH12016501613A1 (en) Pyrazines modulators of gpr6
EP4480577A3 (en) Structured elements and methods of use
MX2020012065A (es) Compuestos de ciclopentano.
IN2014MU00916A (es)
MX2017013156A (es) Metodos para tratar enfermedades.
EA201790321A1 (ru) Эластомерные композиции, содержащие усниновую кислоту, и изделия, изготовленные из них или покрытые ими
MX2019004182A (es) Proceso para la fabricacion de 2,6-dimetil-5-hepten-1-al.
IN2014CH00304A (es)
MX371158B (es) Compuestos inhibidores de pde2.